Vera Therapeutics, Inc. 4

President and CEO Fordyce Marshall sold a total of 46,250 shares of Vera Therapeutics Class A Common Stock on July 7, 2026 for roughly $1.95 million under a Rule 10b5-1 plan.

On July 7, 2026, Vera Therapeutics, Inc. President and CEO Fordyce Marshall executed a series of open-market sales of the company’s Class A Common Stock pursuant to a Rule 10b5-1 trading plan. The transactions consisted of four sale blocks: 1,000 shares at a weighted-average price of approximately $40.78, 32,550 shares at about $42.07, 10,500 shares at about $42.86, and 2,200 shares at about $43.59, for an aggregate of 46,250 shares sold and an estimated total value of roughly $1.95 million. Following these sales, Marshall’s direct holdings decreased but remained significant at 151,994 shares, and he also continued to hold indirect interests of 122,949 shares through a GRAT and 99,081 shares through a trust, preserving substantial exposure to the company’s equity.

Filing Facts

CIK

1831828

Ticker

VERA

Form

4

Source Type

fda

Accession

0001859453-26-000010

Alert Tier

7